Mediators of Inflammation / 2013 / Article / Tab 2

Review Article

Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy

Table 2

Sterile inflammatory rates between anti-VEGF agents.

StudyAnti-VEGF agentNumber of patientsNumber of
Percentage (%) of

Chong et al. (2010) [11]Bevacizumab161160.40%
Georgopoulos et al. (2009) [25]Bevacizumab25000.03%
Shima et al. (2008) [16]Bevacizumab70713000.28%
Wickremasinghe et al. (2008) [10]Bevacizumab12781.49%
Johnson et al. (2010) [26]Bevacizumab1736931.30%
Sato et al. (2010) [22]Bevacizumab353514.3%
Yamashiro et al. (2010) [19]Bevacizumab152073%
Wang et al. (2013) [24]Bevacizumab11611669%
Wu et al. (2008) [27]Bevacizumab117343030.09%
Chong et al. (2010) [11]Ranibizumab38390.03%
Regillo et al. (2008) [28]Ranibizumab1840%
Holz et al. (2011) [29]Ranibizumab5140%
Busbee et al. (2013) [30]Ranibizumab10980.4%
Rosenfeld et al. (2006) [12]Ranibizumab7162.6%
Brown et al. (2006) [13]Ranibizumab2800.35%
Heier et al. (2006) [31]Ranibizumab10511.4%
Antoszyk et al. (2008) [32]Ranibizumab1059.5%
Rosenfeld et al. (2006) [18]Ranibizumab2986%
Chun et al. (2006) [33]Ranibizumab103050%
Chakravarthy et al. (2012) [34] Bevacizumab and ranibizumab6100.16%
Ladas et al. (2009) [35]Bevacizumab and ranibizumab45020001.90%
Sharma et al. (2012) [36]Bevacizumab and ranibizumab52415841.90%
Hahn et al. (2013) [37]Aflibercept300000.05%
Ho et al. (2013) [38]Aflibercept850%
D'Amico et al. (2006) [39]Pegaptanib11900%
Singerman et al. (2008) [40]Pegaptanib16112549%

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.